1. Home
  2. HLP vs ELTX Comparison

HLP vs ELTX Comparison

Compare HLP & ELTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • HLP
  • ELTX
  • Stock Information
  • Founded
  • HLP 2021
  • ELTX 2011
  • Country
  • HLP China
  • ELTX United States
  • Employees
  • HLP N/A
  • ELTX N/A
  • Industry
  • HLP Industrial Machinery/Components
  • ELTX Biotechnology: Pharmaceutical Preparations
  • Sector
  • HLP Industrials
  • ELTX Health Care
  • Exchange
  • HLP Nasdaq
  • ELTX Nasdaq
  • Market Cap
  • HLP 102.1M
  • ELTX 121.7M
  • IPO Year
  • HLP 2023
  • ELTX N/A
  • Fundamental
  • Price
  • HLP $1.62
  • ELTX $10.52
  • Analyst Decision
  • HLP
  • ELTX Strong Buy
  • Analyst Count
  • HLP 0
  • ELTX 2
  • Target Price
  • HLP N/A
  • ELTX $11.00
  • AVG Volume (30 Days)
  • HLP 249.9K
  • ELTX 75.5K
  • Earning Date
  • HLP 09-19-2025
  • ELTX 11-12-2025
  • Dividend Yield
  • HLP N/A
  • ELTX N/A
  • EPS Growth
  • HLP N/A
  • ELTX N/A
  • EPS
  • HLP 0.02
  • ELTX N/A
  • Revenue
  • HLP $16,731,357.00
  • ELTX N/A
  • Revenue This Year
  • HLP N/A
  • ELTX N/A
  • Revenue Next Year
  • HLP N/A
  • ELTX N/A
  • P/E Ratio
  • HLP $70.09
  • ELTX N/A
  • Revenue Growth
  • HLP 19.13
  • ELTX N/A
  • 52 Week Low
  • HLP $0.61
  • ELTX $4.05
  • 52 Week High
  • HLP $1.82
  • ELTX $12.62
  • Technical
  • Relative Strength Index (RSI)
  • HLP 76.04
  • ELTX 44.19
  • Support Level
  • HLP $1.30
  • ELTX $10.18
  • Resistance Level
  • HLP $1.53
  • ELTX $11.48
  • Average True Range (ATR)
  • HLP 0.14
  • ELTX 0.41
  • MACD
  • HLP 0.03
  • ELTX -0.10
  • Stochastic Oscillator
  • HLP 89.83
  • ELTX 24.57

About HLP Hongli Group Inc.

Hongli Group Inc is a cold roll-formed steel profile manufacturer in China. It customizes and manufactures cold roll-formed steel profiles for machinery and equipment in a variety of sectors, including but not limited to mining and excavation, construction, agriculture, and transportation. Geographically, the company generates the majority of its revenue from the PRC.

About ELTX Elicio Therapeutics Inc.

Elicio Therapeutics Inc is a clinical-stage biotechnology company pioneering the development of cancer immunotherapies for patients with limited treatment options and poor outcomes. Its proprietary Amphiphile, or AMP, platform delivers investigational immunotherapeutics directly to the brain center of the immune system the lymph nodes. Its focus is the development of cancer immunotherapies against biologically validated but hard-to-drug targets that can be activated through lymph node trafficking. Elicio is engineering lymph node-targeted AMPlifiers, immunomodulators, adjuvants, and vaccines for an array of aggressive cancers. It has developed its cancer vaccine product candidates to target biologically validated tumor mutation drivers using known neoantigens.

Share on Social Networks: